The four-plate test in mice

Neuromethods

Volumn 63, Issue , 2011, Pages 123-141

  Hascoët, Martine ^a   Bourin, Michel ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Animal model; Anxiolytics; Four plate test; Mice; Receptor ligands

Indexed keywords

ABECARNIL; ALPIDEM; ALPRAZOLAM; BACLOFEN; BRETAZENIL; BROMAZEPAM; CITALOPRAM; CLOZAPINE; DERAMCICLANE; DESIPRAMINE; DIAZEPAM; DOSULEPIN; FLUMAZENIL; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; LORAZEPAM; MAPROTILINE; MIANSERIN; MILNACIPRAN; MOCLOBEMIDE; MUSCIMOL; PAROXETINE; PIRENPERONE; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE;

ANALGESIA; ANXIETY; ARTICLE; DRUG EFFECT; ELECTRIC SHOCK; ENVIRONMENTAL EXPOSURE; EXPERIMENTAL TEST; FOUR PLATE TEST; HOT PLATE TEST; LOCOMOTION; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALIA; MUS;

EID: 80054745688     PISSN: 08932336     EISSN: 19406045     Source Type: Book Series    
DOI: 10.1007/978-1-61779-313-4_8     Document Type: Article

References (94)

1. Boissier JR, Simon P, Aron C (1968) A new method for rapid screening of minor tranquillizers in mice. Eur J Pharmacol 4:145-151
2. Liao JF, Hung WY, Chen CF (2003) Anxiolyticlike effects of baicalein and baicalin in the vogel conflict test in mice. Eur J Pharmacol 464:141-146
3. Umezu T (1999) Effects of psychoactive drugs in the vogel test in mice. Jpn J Pharmacol 80:111-118 (Pubitemid 29329309)
4. Bourin M, Hascoët M, Mansouri B, Colombel MC, Bradwejn J (1992) Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci 17:72-77 (Pubitemid 23141093)
5. Hascoët M and Bourin M (1997) Anticonflict effect of alpidem as compared with the benzodiazepine alprazolam in Rats. Pharmacol Biochem Behav 2:317-324 (Pubitemid 27115921)
6. Jones GH, Schneider C, Schneider HH, Seidler J, Cole BJ and Stephens DN (1994) Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies. Psychopharmacol (Ber) 114:191-199 (Pubitemid 24152105)
7. Sills GJ (2006) The mechanisms of action of gabapentine and pregabalin. Curr Opin Pharmacol. 6:108-113
8. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L (1998) A summary of mechanistic hypotheses of gabapentine pharmacology. Epilepsy Res 29:233-249 (Pubitemid 28137601)
9. Götz E, Feuerstein TJ, Lais A, Meyer DK (1993) Effects of gabapentine on release of gammaaminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 43:636-638 (Pubitemid 23176484)
10. Roberto M, Gilpin NW, O'Dell LE, Cruz MT, Morse AC, Siggins GR, Koob GF (2008) Cellular and behavioral interactions of gabapentine with alcohol dependence. J Neurosci 28:5762-5771
11. Partyka A, Klodzińska A, Szewczyk B, Wierońska JM, Chojnacka-Wj́cik E, Librowski T, Filipek B, Nowak G, Pilc A (2007) Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacol Rep 59:757-762 (Pubitemid 351586569)
12. Feighner JP (1999) Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry 60:18-22 (Pubitemid 30107951)
13. Gorman JM, Kent JM (1999) SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60:33-38
14. Zohar J, Westenberg HG (20004) Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 03:39-49
15. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L (1997) Paroxetine efficacy in the treatment of generalised anxiety disorder. Acta Psychiatr Scand 95: 444-450 (Pubitemid 27244846)
16. File SE (1985). Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology 13:55-62 (Pubitemid 15033658)
17. Linnoila M, Eckhardt M, Durcan M, Lister R, Martin P (1987) Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacology Bull 23:452-457 (Pubitemid 18008451)
18. Chopin P, Briley M (1987) Animal models of anxiety: the effects of compounds that modify 5-HT neurotransmission. TIPS 8:383-389
19. Bourin M, Redrobe JP, Hascoet M, Colombel MC, Baker GB (1996) A schematic representation of the psychopharmacological profile ofantidepressa ts. Prog Neuro-Psychopharmacol Biol Psychiat 20:1389-1402 (Pubitemid 26412842)
20. Handley SL, McBlane JW (1992) Opposite effects of fluoxetine in two animal models of anxiety. Br J Pharmacol 107:446P (suppl)
21. Hascoët M, Bourin M, Colombel MC, Fiocco AJ, Baker GB (2000) Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 65:339-344 (Pubitemid 30100282)
22. Hyttel J (1996) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9:19-26
23. Redrobe JP, Bourin M, Colombel MC, Baker GB(1998) Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 138:1-8 (Pubitemid 28319041)
24. Griebel G (1996) Variability in the effect of 5-HT related compounds in experimental models of anxiety : evidence for multiple mechanism of 5-HT in anxiety or never-ending story?. Polish J Pharmacol 48: 129-136 (Pubitemid 26246605)
25. Eison MS (1989) The new generation of serotonergic anxiolytics: possible clinical roles. Psychopathology 22:13-20 (Pubitemid 19104665)
26. Ables AZ, Baughman OL 3rd (2003) Antidepressants: update on new agents and indications. Am Fam Physician 67:547-554 (Pubitemid 36182179)
27. Bourin M, Lambert O (2002) Pharmacotherapy of anxious disorders. Hum Psychopharmacol 17:383-400 (Pubitemid 35469348)
28. Nemeroff CB (2003) Anxiolytics: past,present, and future agents. J Clin Psychiatry 64:3-6 (Pubitemid 36389865)
29. Vaswani M, Linda FK, Ramesh S (2003) Role of selective serotonin reuptake inhibitors in sychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85-102 (Pubitemid 36131110)
30. Lucki I (1996) Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry 7:5-10 (Pubitemid 26271943)
31. Passchier J, van Waarde A (2001) Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system. Eur J Nucl Med 28:113-129 (Pubitemid 32120814)
32. Bell C, Abrams J, Nutt D (2001) Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178:399-405 (Pubitemid 32436803)
33. Murphy DL, Wichems C, Li Q, Heils A (1999) Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Trends Pharmacol Sci 20:246-252 (Pubitemid 29295174)
34. Zhuang X, Gross C, Santarelli L, Compan V, Trillat AC, Hen R (1999) Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 21:52 S-60 S (Pubitemid 29396471)
35. Griebel G (1995) 5-Hydroxytryptamineinteracting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319-395
36. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83-244. (Pubitemid 37309295)
37. Hascoët M, Bourin M, Couetoux du Tertre A (1997) Influence of prior experience on mice behavior using the four-plate test. Pharmacol Biochem Behav 58:1131-1138 (Pubitemid 28108226)
38. Hascoët M, Bourin M, Nic Dhonnchadha BA (2000) The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacol Biochem Behav 67:45-53
39. Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 92:14-24 (Pubitemid 17063656)
40. Hensman R, Guimarães FS, Wang M, Deakin JF (1991) Effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology (Berl) 104:220-224
41. Griebel G, Perrault G, Sanger DJ (1997) A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36:793-802 (Pubitemid 27286733)
42. Nic Dhonnchadha BA, Bourin M, Hascoët M (2003) Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res 140:203-214 (Pubitemid 36321745)
43. Nic Dhonnchadha BA, Hascoët M, Jolliet P, Bourin M (2003) Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res 147:175-184 (Pubitemid 37492991)
44. Borsini F, Brambilla A, Cesana R, Donetti A (1993) The effect of DAU 6215, a novel 5HT-3 antagonist, in animal models of anxiety. Pharmacol Res 27:151-164 (Pubitemid 23123055)
45. Dooley DJ, Klamt I (1993) Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test. Psychopharmacology (Berl) 112:452-454 (Pubitemid 23324166)
46. Klodzińska A, Tatarczyńska E, Stachowicz K, Chojnacka-Wj́cik E (2004) The anxiolyticlike activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist. J Physiol Pharmacol 55:113-126 (Pubitemid 38524218)
47. Klodzińska A, Chojnacka-Wj́cik E, Palucha A, Brański P, Popik P, Pilc A (1999) Potential antianxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38:1831-1839 (Pubitemid 29509721)
48. Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE (2007) Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon. Neuropeptides 41:307-320 (Pubitemid 47247864)
49. Klodzinska A, Tatarczyńska E, Chojnacka-Wj́cik E, Nowak G, Cosford ND, Pilc A (2004) Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 47:342-350 (Pubitemid 38953225)
50. Tatarczyńska E, Klodzińska A, Chojnacka-Wj́cik E, Palucha A, Gasparini F, Kuhn R, Pilc A (2001) Potential anxiolytic- and antidepressant- like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132:1423-1430 (Pubitemid 32281030)
51. Stachowicz K, Brañski P, Klak K, van der Putten H, Cryan JF, Flor PJ, Andrzej P (2008) Selective activation of metabotropic G-proteincoupled glutamate 7 receptor elicits anxiolyticlike effects in mice by modulating GABAergic neurotransmission. Behav Pharmacol 19:597-603
52. Sanger DJ, Joly D (1991) The effects of NMDA antagonists on punished exploration in mice. Behav Pharmacol 2:57-63
53. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, SoubriëtP (2002) 4-(2-Chloro-4-methoxy- 5-methylphenyl)-N-[(1 S)-2-cyclopropyl-1- ( 3 - f l u o r o - 4 - m e t h y l p h e n y l ) e t h y l ] 5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333-345 (Pubitemid 34250312)
54. Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring RH (2008) Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) 197: 601-611
55. Serradeil-Le Gal C, Wagnon J 3 rd, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005) An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev 11:53-68 (Pubitemid 40577945)
56. Przegaliński E, Tatarczyńska E, Chojnacka- Wj́cik E (1998) Anxiolytic- and antidepressantlike effects of an antagonist at glycineB receptors. Pol J Pharmacol 50:349-354
57. Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosenzweig-Lipson S (2006) Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl) 185:218-225 (Pubitemid 43363618)
58. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S (2007) Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant- like effects. Neuropsychopharmacology 32:2360-2368 (Pubitemid 47587671)
59. Hughes ZA, Liu F, Platt BJ, Dwyer JM, Pulicicchio CM, Zhang G, Schechter LE, Rosenzweig-Lipson S, Day M (2008) WAY- 200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/ antidepressant agent. Neuropharmacology 54:1136-1142
60. Foreman MM, Hanania T, Eller M (2009) Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in the four plate conflict test. Eur J Pharmacol 14:602:316-320
61. Stemmelin J, Cohen C, Terranova JP, Lopez- Grancha M, Pichat P, Bergis O, Deobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G (2008) Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33:574-587
62. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (2006) Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51:578-586 (Pubitemid 44215962)
63. Wesolowska A, Nikiforuk A (2007) Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 52:1274-1283 (Pubitemid 46527703)
64. Grisel JE, Fleshner M, Watkins LR, Maier SF (1993) Opioid and nonopioid interactions in two forms of stress-induced analgesia. Pharmacol Biochem Behav 45:161-172
65. Fardin V, Oliveras JL, Besson JM (1984) A reinvestigation of the analgesic effects induced by stimulation of the periaqueductal gray matter in the rat: IR The production of behavioral side effects together with analgesia. Brain Res 306:105-123 (Pubitemid 14090449)
66. Jacob JJ, Tremblay EC, Colombel MC (1994) Enhancement of nociceptive reactions by naloxone in mice and rats. Psychopharmacologia 37:217-223
67. Espejo EF, Mir D (1993) Structure of the rat's behaviour in the hot plate test. Behav Brain Res 56:171-176 (Pubitemid 23305199)
68. Espejo EF, Stinus L, Cador M, Mir D (1994) Effects of morphine and naloxone on behaviour in the hot plate test: an ethopharmacological study in the rat. Psychopharmacology 113:500-510 (Pubitemid 24150501)
69. Ripoll N, Hascoët M, Bourin M (2006) The four-plates test: anxiolytic or analgesic paradigm? Prog Neuropsychopharmacol Biol Psychiatry 30:873-880 (Pubitemid 43795375)
70. Drugan RC, Ryan SM, Minor TR, Maier SF (1984) Librium prevents the analgesia and shuttlebox escape deficit typically observed following inescapable shock. Pharmacol Biochem Behav 21:749-754 (Pubitemid 15203855)
71. Gatch MB (1999) Effects of benzodiazepines on acute and chronic ethanol-induced nociception in rats. Alcohol Clin Exp Res 23:1736-1743
72. Nadeson R, Guo Z, Porter V, Gent JP, Goodchild CS (1996) Gamma-aminobutyric acidA receptors and spinally mediated antinociception in rats. J Pharmacol Exp Ther 278:620-626
73. Pakulska W, Czarnecka E (2001) Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice. Pharmazie 56:89-91 (Pubitemid 32099551)
74. Rosland JH, Hole K (1990) Benzodiazepineinduced antagonism of opioid antinociception may be abolished by spinalization or blockade of the benzodiazepine receptor. Pharmacol Biochem Behav 37:505-509
75. Borges PC, Coimbra NC, Brandao ML (1988) Independence of aversive and pain mechanisms in the dorsal periaqueductal gray matter of the rat. Braz J Med Biol Res 21:1027-1031
76. Fasmer OB, Hunskaar S, Hole K (1989) Antinociceptive effects of serotonergic reuptake nhibitors in mice. Neuropharmacology 28:1363-1366 (Pubitemid 20008272)
77. Otsuka N, Kiuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A (2001) Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. J Anesth 15:154-158 (Pubitemid 32899058)
78. Yokogawa F, Kiuchi Y, Ishikawa Y, Otsuka N, Masuda Y, Oguchi K, et al.(2002) An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg 95:163-168 (Pubitemid 34705572)
79. Okuda K, Takanishi T, Yoshimoto K, Ueda S (2003) Trazodone hydrochloride attenuates thermal hyperalgesia in a chronic constriction injury rat model. Eur J Anaesthesiol 20:409-415 (Pubitemid 36597047)
80. Schreiber S, Backer MM, Herman I, Shamir D, Boniel T, Pick CG (2000) The antinociceptive effect of trazodone in mice is mediated through both mu-opioid and serotonergic mechanisms. Behav Brain Res 114:51-56
81. Bourin M, Masse F, Dailly E, Hascoët M (2005) Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action. Pharmacol Biochem Behav 81:645-656 (Pubitemid 40973787)
82. David DJ, Renard CE, Jolliet P, Hascoet M, Bourin M (2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 166:373-382 (Pubitemid 36503032)
83. Prado WA, Roberts MH (1985) An assessment of the antinociceptive and aversive effects of stimulating identified sites in the rat brain. Brain Res 340:219-228 (Pubitemid 15226699)
84. Beyer CE, Dwyer JM, Platt BJ, Neal S, Luo B, Ling HP, Lin Q, Mark RJ, Rosenzweig- Lipson S, Schechter LE (2010) Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation. Psychopharmacology (Berl) 209:303-311
85. Czopek A, Byrtus H, Kolaczkowski M, Pawlowski M, Dybala M, Nowak G, Tatarczyńska E, Wesolowska A, Chojnacka- Wj́cik E (2010) Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity. Eur J Med Chem 45:1295-1303
86. MassëtF, Hascoët M, Bourin M (2005) alpha2- Adrenergic agonists antagonise the anxiolyticlike effect of antidepressants in the four-plate test in mice. Behav Brain Res 164:17-28 (Pubitemid 41253728)
87. Massé F, Hascoë M, Dailly E, Bourin M (2006) Effect of noradrenergic system on the anxiolytic- like effect of DOI (5-HT2A/2 C agonists) in the four-plate test. Psychopharmacology (Berl) 83:471-481 (Pubitemid 41721149)
88. Nic Dhonnchadha BA, Ripoll N, Clenet F, Hascoët M, Bourin M (2005) Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology (Berl) 179:418-429 (Pubitemid 40569045)
89. Ripoll N, Hascoët M, Bourin M (2006) Implication of 5-HT(2A) subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behav Brain Res 166:131-139 (Pubitemid 41677369)
90. MassëtF, Petit-Déoulièe B, Dubois I, Hascoët M, Bourin M (2008) Anxiolytic-like effect of DOI microinjections into the hippocampus (but not the amygdala nor the PAG) in the mice test. Behav. Brain Res 188: 291-297
91. Petit-Demoulièe B, MassëtF, Cogrel N, Hascoët M, Bourin M (2009) Brain structuresimplicated in the four-plate test in naëte and experienced Swiss mice using injection of diazepam and the 5-HT2A agonist DOI. Behav Brain Res 204:200-205
92. Ripoll N, Nic Dhonnchadha BA, Séille V, Bourin M, Hascoët M (2005) The four-plates test-retest paradigm to discriminate anxiolytic effects. Psychopharmacology (Berl) 180: 73-83 (Pubitemid 40897073)
93. File SE (1990) "One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze." Psychopharmacology (Berl) 100:281-282 (Pubitemid 20038575)
94. Petit-Demoulièe B, Hascoët M, Bourin M (2008) Factors triggering abolishment of benzodiazepines effects in the Four-Plate Test- retest in mice. Eur Neuropsychopharmacol 18:41-47 (Pubitemid 350213384)